Casdin Capital’s Ovid Therapeutics OVID Stock Holding History

Casdin Capital’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-160,000	Closed	-$1.58M	–	34
2017 Q4	$1.58M	Sell	160,000 -47,500	-23%	-$436K	0.38%	26
2017 Q3	$1.78M	Sell	207,500 -14,200	-6%	-$118K	0.5%	26
2017 Q2	$2.33M	Buy	+221,700	New	+$2.89M	0.86%	28

Other funds holding OVID

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Casdin Capital's OVID Position: Q1 2018 in Review

Casdin Capital sold out of Ovid Therapeutics (OVID) in Q1 2018, closing a stake of 160,000 shares — an estimated $1.58M sold.

Casdin Capital first reported a position in OVID in Q2 2017 and held it in 3 quarters. The position peaked at $2.33M in Q2 2017. 48 funds tracked by Wall St. Rank hold OVID as of Q1 2018.

Casdin Capital reported no remaining Ovid Therapeutics position as of Q1 2018 after selling out during the quarter.
Casdin Capital sold 160,000 Ovid Therapeutics shares in Q1 2018, an estimated $1.58M.
Casdin Capital first reported a position in Ovid Therapeutics in Q2 2017 and held it in 3 quarters.
Casdin Capital's Ovid Therapeutics position peaked at $2.33M in Q2 2017.
48 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2018.

Based on Casdin Capital's 13F filing for Q1 2018, filed 15 May 2018.